Ban's AI-powered smart glasses remain surprisingly popular, while others have failed. Can you add prescription lenses to your ...

The Rxsight® Light Adjustable Lens system, including the LAL™/LAL+®, and the Rxsight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens ...

A years-long audit of the construction of the embattled Southwest Light Rail line has concluded ... which is now expected to cost taxpayers $2.86 billion. The presentation by the Office of the ...

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the ...

RxSight (NASDAQ:RXST ... manufacture and sale of light adjustable lenses and related capital equipment. Market Capitalization Perspectives: The company's market capitalization falls below industry ...

These factors led to a year-over-year decline in same-store sales of Light Adjustable Lenses (LALs ... clinical data to highlight the benefits of RxSight’s adjustable IOL platform.

BofA has lowered the price target from $36 to $22. RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+) in the first quarter, missing Street estimates by 9%. The year over year ...

Sold 27,579 Light Adjustable Lenses (LALs), up 36% year-over-year. LDD installed base increased to 1,044 units, up 43% year-over-year. RxSight revised its 2025 revenue guidance to $160-175 million, ...

Sold 27,579 Light Adjustable Lenses (LALs), up 36% year-over-year. LDD installed base increased to 1,044 units, up 43% year-over-year. RxSight revised its 2025 revenue guidance to $160-175 million ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...